Skip to content
QurAlisQurAlis
  • About Us Expand
    • About QurAlis
    • People
    • Partners & Investors
    • Contact Us
  • Platform Expand
    • Antisense Oligonucleotides
    • Patient-derived disease models
    • References
  • ALS Programs Expand
    • Our Programs
    • Excitotoxicity
    • Autophagy
    • TDP43
  • Patients Expand
    • ALS Patients
    • A Message of Hope
    • ALS News
  • News Expand
    • Press Releases
    • QurAlis News
  • Careers Expand
    • Careers
QurAlisQurAlis

Press Releases

Home
News
Press Releases
December 11, 2020
QurAlis’ Selective Kv7 Opener, a Drug Candidate for ALS, Demonstrates up to 20-Fold Increase in Potency and Dramatic Reduction in Side Effects Compared to Retigabine in Preclinical Models
December 2, 2020
QurAlis to Present Data on Two Precision Medicine Programs (Kv7 and TBK1) at MNDA 31st International Symposium on ALS/MND
October 29, 2020
QurAlis Announces Appointment of new Chief Medical Officer and Formation of Clinical Advisory Board
July 1, 2020
QurAlis Announces Agreement to Strengthen ALS Pipeline
May 13, 2020
QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS)
April 5, 2018
QurAlis Launches with Seed Funding from MPH, Amgen and Alexandria, united in the fight to cure ALS

100 Cambridge Park Drive, 5th Floor
Cambridge, MA 02140, USA
781-816-7031
info@quralis.com

  • About Us
  • Platform
  • ALS Programs
  • Patients
  • News
  • Careers
Menu
  • About Us
  • Platform
  • ALS Programs
  • Patients
  • News
  • Careers

© 2021 QurAlis LLC | Privacy Policy | Terms of Use

  • About Us
    • About QurAlis
    • People
    • Partners & Investors
    • Contact Us
  • Platform
    • Antisense Oligonucleotides
    • Patient-derived disease models
    • References
  • ALS Programs
    • Our Programs
    • Excitotoxicity
    • Autophagy
    • TDP43
  • Patients
    • ALS Patients
    • A Message of Hope
    • ALS News
  • News
    • Press Releases
    • QurAlis News
  • Careers
    • Careers